Research

Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell derived lung and cerebral organoids

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Assessing the influence of climate on wintertime SARS-CoV-2 outbreaks

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Reduction in mobility and COVID-19 transmission

Global absence and targeting of protective immune states in severe COVID-19

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial

For March 2021, we have selected: Krienke C. et al., A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021; 371: 145-153. doi: 10.1126/science.aay3638.